Full history for every metric is available with a Kvantra account
PLx Pharma Inc. (PLXP)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1 | 1 | 1 | 0 | 8 | 5 |
| Operating profit | $m | -41 | -40 | |||||
| Net profit | $m | -21 | -15 | 1 | -21 | -15 | -51 | -15 |
| EPS reported | $ | -2.18 | -0.54 | |||||
| Operating cashflow per share | $ | -1.36 | -1.36 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.36 | -1.36 | |||||
| Free cash flow | $m | -32 | -59 | |||||
| Net debt | $m | -69 | -26 | |||||
| Book value equity | $m | 52 | 26 | |||||
| Book value per share | $ | 2.19 | 0.92 | |||||
| Number of shares | m | 23.65 | 28.6 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.67 | 0.10 | |||||
| P/S LTM | x | 23.08 | 0.56 | |||||
| P/FCF LTM | x | -5.90 | -0.04 | |||||
| EV/EBITDA LTM | x | -3.41 | 0.86 | |||||
| EV/Sales LTM | x | 14.63 | -5.13 | |||||
| Earnings Yield LTM | % | -27.16% | -2501.0% | |||||
| FCF Yield | % | -16.95% | -2340.7% | |||||
| Quality | ||||||||
| ROE | % | -99.57% | -165.64% | |||||
| ROIC | % | -62.98% | -62.98% | |||||
| Operating margin | % | -496.95% | -496.95% | |||||
| Gross margin | % | 41.46% | 41.46% | |||||
| FCF/Sales | % | -391.30% | -391.30% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -31.32% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.97 | 1.97 | |||||
| EBIT/Net interest | x | -40,790.00 | -40,790.00 | |||||
| Net debt/market cap | % | -36.63% | -1019.1% | |||||
| Net debt/Equity | x | -1.34 | -0.99 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the management of pain and inflammation. Additionally, they provide Vazalore 81 mg in the form of liquid-filled aspirin capsules. Looking ahead, their product development pipeline features PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, both of which are in Phase I clinical trials for addressing pain, inflammation, and fever. PLx Pharma makes its products available to consumers through a variety of retail avenues, including pharmacies, major retailers, supermarkets, and online sales channels. Founded in 2002, PLx Pharma Inc. is headquartered in Sparta, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PLx Pharma Inc. (PLXP)
PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the management of pain and inflammation. Additionally, they provide Vazalore 81 mg in the form of liquid-filled aspirin capsules. Looking ahead, their product development pipeline features PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, both of which are in Phase I clinical trials for addressing pain, inflammation, and fever. PLx Pharma makes its products available to consumers through a variety of retail avenues, including pharmacies, major retailers, supermarkets, and online sales channels. Founded in 2002, PLx Pharma Inc. is headquartered in Sparta, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free